SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Oxygenta Pharma - Quaterly Results

20 May 2022 Evaluate
The sales moved down -36.21% to Rs. 70.76 millions for the March 2022 quarter as compared to Rs. 110.92 millions during the corresponding quarter last year.The Net Loss for the quarter ended March 2022 is Rs. -9.13 millions as compared to Net Profit of Rs. 8.08 millions of corresponding quarter ended March 2021Operating profit Margin for the quarter ended March 2022 slipped to -14.30% as compared to 5.87% of corresponding quarter ended March 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 70.76 110.92 -36.21 605.25 520.27 16.33 605.25 520.27 16.33
Other Income 0.03 0.68 -95.59 0.05 0.91 -94.51 0.05 0.91 -94.51
PBIDT -14.30 5.87 -343.61 14.81 39.34 -62.35 14.81 39.34 -62.35
Interest 1.64 13.25 -87.62 9.25 17.83 -48.12 9.25 17.83 -48.12
PBDT -4.10 14.51 -128.26 11.02 43.40 -74.61 11.02 43.40 -74.61
Depreciation 3.82 4.29 -10.96 15.91 11.96 33.03 15.91 11.96 33.03
PBT -7.92 10.22 -177.50 -4.89 31.44 -115.55 -4.89 31.44 -115.55
TAX 1.21 2.14 -43.46 1.21 2.14 -43.46 1.21 2.14 -43.46
Deferred Tax 1.21 2.14 -43.46 1.21 2.14 -43.46 1.21 2.14 -43.46
PAT -9.13 8.08 -213.00 -6.10 29.30 -120.82 -6.10 29.30 -120.82
Equity 142.01 102.01 39.21 142.01 102.01 39.21 142.01 102.01 39.21
PBIDTM(%) -20.21 5.29 -481.87 2.45 7.56 -67.64 2.45 7.56 -67.64

Oxygenta Pharma Share Price

56.23 -0.75 (-1.32%)
20-Apr-2026 14:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.15
Dr. Reddys Lab 1234.30
Cipla 1232.95
Zydus Lifesciences 938.40
Lupin 2329.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×